News · 26 weeks22+500%
2026-03-012026-08-23
Mix990d
- SEC Filings4(44%)
- Insider3(33%)
- Earnings2(22%)
Latest news
25 items- INSIDERDirector Sachetta Eric bought $112,904 worth of shares (34,697 units at $3.25), increasing direct ownership by 20% to 209,310 units (SEC Form 4)4 - Sensus Healthcare, Inc. (0001494891) (Issuer)
- INSIDERCHIEF EXECUTIVE OFFICER Sardano Joseph C bought $60,486 worth of shares (20,000 units at $3.02), increasing direct ownership by 2% to 1,220,293 units (SEC Form 4)4 - Sensus Healthcare, Inc. (0001494891) (Issuer)
- INSIDERDirector Sachetta Eric bought $97,850 worth of shares (31,000 units at $3.16), increasing direct ownership by 22% to 174,613 units (SEC Form 4)4 - Sensus Healthcare, Inc. (0001494891) (Issuer)
- SECSEC Form 10-Q filed by Sensus Healthcare Inc.10-Q - Sensus Healthcare, Inc. (0001494891) (Filer)
- PRSensus Healthcare Reports Second Quarter 2026 Financial Results and Business HighlightsCommercial Momentum Builds Following CPT Code Implementation Revenue Recognition on Eight Purchased Units Shifted to Q3 Due to Financing Approval Timing CMS Proposed 26% Increase in Hospital-Based Delivery Code, Further Strengthening the Reimbursement Outlook for SRT Customer Adoption, Pipeline Development and Commercial Expansion Advanced Across U.S. and International Markets Company Remains Focused on Delivering Strong Second Half Performance Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced financial results and business highlights
- SECSensus Healthcare Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Sensus Healthcare, Inc. (0001494891) (Filer)
- PRSensus Healthcare to Report Second Quarter 2026 Financial Results and Hold Business Update Conference Call on August 13, 2026Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced the company will report financial results for the second quarter of 2026 on Thursday, August 13, 2026. Management will hold a conference call beginning at 4:30 pm Eastern time to review the results, provide a business update and answer questions.Participants are encouraged to pre-register for the conference call using this link to receive a unique dial-in number to bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Those unable to pr
- SECSensus Healthcare Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Sensus Healthcare, Inc. (0001494891) (Filer)
- SECSensus Healthcare Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Sensus Healthcare, Inc. (0001494891) (Filer)
- SECSEC Form 10-Q filed by Sensus Healthcare Inc.10-Q - Sensus Healthcare, Inc. (0001494891) (Filer)
- INSIDERDirector Sachetta Eric bought $5,002 worth of shares (1,500 units at $3.33), increasing direct ownership by 1% to 143,613 units (SEC Form 4)4 - Sensus Healthcare, Inc. (0001494891) (Issuer)
- SECSensus Healthcare Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Sensus Healthcare, Inc. (0001494891) (Filer)
- PRSensus Healthcare Reports First Quarter 2026 Financial Results and Business HighlightsDedicated CPT Codes for Superficial Radiotherapy (SRT) Now Effective, Driving Increased Customer Activity, Customer Diversification and Improved Physician Economics Sales Pipeline and Financing Activity Strengthen Following Reimbursement Clarity Expansion of Installed Base and Recurring Revenue Growth Driving Advancement Towards Profitability Exited the Quarter with $18.3 Million in Cash and No Debt Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced financial results and business highlights for the three months ended March 31, 2026. Hig
- SECSEC Form DEF 14A filed by Sensus Healthcare Inc.DEF 14A - Sensus Healthcare, Inc. (0001494891) (Filer)
- PRSensus Healthcare to Report First Quarter 2026 Financial Results and Hold Business Update Conference Call on May 7, 2026Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced the company will report financial results for the first quarter of 2026 on Thursday, May 7, 2026. Management will hold a conference call beginning at 4:30 pm Eastern time to review the results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a unique dial-in number to bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Those unable to pre
- INSIDERAmendment: SEC Form 4 filed by Sachetta Eric4/A - Sensus Healthcare, Inc. (0001494891) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Rampolla Javier4/A - Sensus Healthcare, Inc. (0001494891) (Issuer)
- INSIDERAmendment: SEC Form 3 filed by new insider Martinez Magdalena3/A - Sensus Healthcare, Inc. (0001494891) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Martinez Magdalena4/A - Sensus Healthcare, Inc. (0001494891) (Issuer)
- PRSensus Healthcare Files Lawsuit Against SkinCure Oncology for Breach of ContractSensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the filing of a lawsuit in the Circuit Court for the Fifteenth Judicial Circuit in and for Palm Beach County, Florida, against SkinCure Oncology, LLC (SkinCure) alleging breach of contract related to unpaid amounts owed for Sensus products that have been delivered, accepted and deployed into clinical use. The complaint alleges that SkinCure has failed to remit millions of dollars for medical equipment that SkinCure has used since August 2025, but now refuses to p
- ANALYSTAlliance Global Partners initiated coverage on Sensus Healthcare with a new price targetAlliance Global Partners initiated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $7.50
- SECSEC Form 10-K filed by Sensus Healthcare Inc.10-K - Sensus Healthcare, Inc. (0001494891) (Filer)
- INSIDERDirector Sachetta Eric bought $7,620 worth of shares (2,000 units at $3.81), increasing direct ownership by 1% to 142,113 units (SEC Form 4)4 - Sensus Healthcare, Inc. (0001494891) (Issuer)
- PRSensus Healthcare Introduces Sensus Link, Brings Advanced Operating Capabilities to the SRT-100™ Installed BaseProprietary cloud-based software and add-on solution designed to provide current and future SRT-100 users with enhanced workflow, operating intelligence and clinical utility Creates a scalable, recurring-revenue opportunity for Sensus tied to treatment workflows and necessary oversight services Supports improved unit economics and expands Sensus' ability to serve Fair Deal Agreement customers and those who purchase a system Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, introduces Sensus Link, a cloud-based software and
- INSIDERSEC Form 3 filed by new insider Biscotti Larry Joseph3 - Sensus Healthcare, Inc. (0001494891) (Issuer)
SRTS FAQ
7 questionsWhat does Sensus Healthcare Inc. do?
Sensus Healthcare, Inc. manufactures, distributes, and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides...Where does SRTS stock trade?
Sensus Healthcare Inc. (SRTS) is listed on NASDAQ.What sector and industry is SRTS in?
Sensus Healthcare Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Sensus Healthcare Inc. go public?
Sensus Healthcare Inc. (SRTS) completed its IPO in 2016.What are analysts saying about SRTS?
Sensus Healthcare Inc. has had 8 recent analyst actions on file. The most recent action was from Alliance Global Partners: Buy with a $750.00 price target on 2026-03-06. Recent price targets range from $700.00 to $1800.00.What companies are similar to SRTS?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare SRTS side-by-side with any of them on Quantisnow.How can I track SRTS on Quantisnow?
Quantisnow aggregates Sensus Healthcare Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SRTS to receive live email and push alerts on every new disclosure.